Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD9793 Intravenous (IV) monotherapy
AZD9793 monotherapy · 1 trial · 1 indication
Number of patients with adverse events by system organ class and preferred term
Number of patients with serious adverse events by system organ class and preferred term
Number of patients with adverse events of special interest by system organ class and preferred term
Number of AEs that in the opinion of the Investigator or the Sponsor contraindicate further dosing or AEs that meet criteria for discontinuation
Number of patients with at least 1 DLT. A DLT is a toxicity as defined in the protocol that occurs from the first dose of study drug up to and including the planned end of the DLT evaluation period that is assessed as unrelated to the disease or disease-related processes under investigation.
The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose expansion only.
| Arm | Type | Description |
|---|---|---|
| Module 1: AZD9793 Intravenous (IV) monotherapy Part A | EXPERIMENTAL | Module 1: AZD9793 Intravenous (IV) monotherapy Part A: Dose Escalation |
| Module 2: AZD9793 Subcutaneous (SC) monotherapy Part A | EXPERIMENTAL | Module 2: AZD9793 Subcutaneous (SC) monotherapy Part A: Dose Escalation |
| Module 1: AZD9793 Intravenous (IV) monotherapy Part B | EXPERIMENTAL | Module 1: AZD9793 Intravenous (IV) monotherapy Part B: Dose Expansion |
| Module 2: AZD9793 Subcutaneous (SC) monotherapy Part B | EXPERIMENTAL | Module 2: AZD9793 Subcutaneous (SC) monotherapy Part B: Dose Expansion |
| Name | Type | Description |
|---|---|---|
| AZD9793 Intravenous (IV) monotherapy | DRUG | T cell-engaging antibody that targets GPC3 on tumour cells |
| AZD9793 Subcutaneous (SC) monotherapy | DRUG | T cell-engaging antibody that targets GPC3 on tumour cells |
Key Inclusion Criteria: * Age ≥ 18 at the time of signing the informed consent. * GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay. Patients who previously received any therapy targeting GPC3 must undergo central laboratory GPC3 testing on tumour ...
AZD9793 is an investigational small molecule being studied for the treatment of hepatocellular carcinoma, a type of liver cancer. It is currently in Phase 1 clinical development as a monotherapy for patients with advanced or metastatic solid tumors, including hepatocellular carcinoma.
The specific molecular target of AZD9793 has not been disclosed in available information. It is described as a small molecule therapeutic being evaluated in a first-in-human study for advanced or metastatic solid tumors, including hepatocellular carcinoma.
AZD9793 is being developed by AstraZeneca PLC, a global biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 1 clinical trial to evaluate the drug as a monotherapy in patients with hepatocellular carcinoma.
AZD9793 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is a first-in-human study designed to evaluate the safety, tolerability, and preliminary efficacy of AZD9793 in participants with advanced or metastatic solid tumors.
AZD9793 is being studied in a single Phase 1 clinical trial with the identifier NCT06795022. This first-in-human study is recruiting participants with hepatocellular carcinoma and is being conducted in the United States, China, Hong Kong, Japan, South Korea, Spain, and Taiwan. The trial aims to enroll 304 participants aged 18 years and older.
Yes, AZD9793 is also known as AZD9793 Intravenous (IV) monotherapy. This alternative name reflects the route of administration and the fact that it is being studied as a single agent, without combination with other therapies, in the ongoing clinical trial.